A Study of LY3381916 Alone or in Combination With LY3300054 in Participants With Solid Tumors
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Solid Tumor|Non Small Cell Lung Cancer|Renal Cell Carcinoma|Triple Negative Breast Cancer
Interventions: DRUG: LY3381916|DRUG: LY3300054
Sponsor: Eli Lilly and Company